Activity-based probes for functional interrogation of retaining β-glucuronidases

Nature Chemical Biology

Volumn 13, Issue 8, 2017, Pages 867-873

  Wu, Liang ^a   Jiang, Jianbing ^b   Jin, Yi ^a   Kallemeijn, Wouter W ^b   Kuo, Chi Lin ^b   Artola, Marta ^b   Dai, Wei ^b   Van Elk, Cas ^b   Van Eijk, Marco ^b   Van Der Marel, Gijsbert A ^b   Codée, Jeroen D C ^b   Florea, Bogdan I ^b   Aerts, Johannes M F G ^b   Overkleeft, Herman S ^b   Davies, Gideon J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; ENZYME INHIBITOR; FLUORESCENT DYE;

ACIDOBACTERIUM CAPSULATUM; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; FIBROBLAST; HEK293T CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR PROBE; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS; SYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; HEK293 CELL LINE; METABOLISM; STRUCTURE ACTIVITY RELATION;

ENZYME INHIBITORS; FLUORESCENT DYES; GLUCURONIDASE; HEK293 CELLS; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85028602331     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2395     Document Type: Article

References (60)

1. Khan, F.I. et al. Large scale analysis of the mutational landscape in β-glucuronidase: a major player of mucopolysaccharidosis type VII. Gene 576, 36-44 (2016).
2. Sly, W.S., Quinton, B.A., McAlister, W.H. & Rimoin, D.L. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J. Pediatr. 82, 249-257 (1973).
3. Naz, H. et al. Human β-glucuronidase: structure, function, and application in enzyme replacement therapy. Rejuvenation Res. 16, 352-363 (2013).
4. Rivara, S., Milazzo, F.M. & Giannini, G. Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med. Chem. 8, 647-680 (2016).
5. Vlodavsky, I. et al. Significance of heparanase in cancer and inflammation. Cancer Microenviron. 5, 115-132 (2012).
6. Cantarel, B.L. et al. The Carbohydrate-Active EnZymes database (CAZy): an expert resource for glycogenomics. Nucleic Acids Res. 37, D233-D238 (2009).
7. Jain, S. et al. Structure of human beta-glucuronidase reveals candidate lysosomal targeting and active-site motifs. Nat. Struct. Biol. 3, 375-381 (1996).
8. Wu, L., Viola, C.M., Brzozowski, A.M. & Davies, G.J. Structural characterization of human heparanase reveals insights into substrate recognition. Nat. Struct. Mol. Biol. 22, 1016-1022 (2015).
9. Jiang, J. et al. Detection of active mammalian GH31 α-glucosidases in health and disease using in-class, broad-spectrum activity-based probes. ACS Cent. Sci. 2, 351-358 (2016).
10. Kallemeijn, W.W. et al. Novel activity-based probes for broad-spectrum profiling of retaining β-exoglucosidases in situ and in vivo. Angew. Chem. Int. Ed. Engl. 51, 12529-12533 (2012).
11. Willems, L.I. et al. Potent and selective activity-based probes for GH27 human retaining α-galactosidases. J. Am. Chem. Soc. 136, 11622-11625 (2014).
12. Witte, M.D. et al. Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat. Chem. Biol. 6, 907-913 (2010).
13. Jiang, J. et al. In vitro and in vivo comparative and competitive activity-based protein profiling of GH29 α-L-fucosidases. Chem. Sci. 6, 2782-2789 (2015).
14. Kwan, D.H. et al. Chemoenzymatic synthesis of 6-phospho-cyclophellitol as a novel probe of 6-phospho-β-glucosidases. FEBS Lett. 590, 461-468 (2016).
15. Barglow, K.T. & Cravatt, B.F. Activity-based protein profiling for the functional annotation of enzymes. Nat. Methods 4, 822-827 (2007).
16. Li, K.Y. et al. Exploring functional cyclophellitol analogues as human retaining beta-glucosidase inhibitors. Org. Biomol. Chem. 12, 7786-7791 (2014).
17. Koshland, D.E. Stereochemistry and the mechanism of enzymatic reactions. Biol. Rev. Camb. Philos. Soc. 28, 416-436 (1953).
18. Willems, L.I. et al. From covalent glycosidase inhibitors to activity-based glycosidase probes. Chemistry 20, 10864-10872 (2014).
19. Michikawa, M. et al. Structural and biochemical characterization of glycoside hydrolase family 79 β-glucuronidase from Acidobacterium capsulatum. J. Biol. Chem. 287, 14069-14077 (2012).
20. Baici, A., Schenker, P., Wächter, M. & Rüedi, P. 3-Fluoro-2,4-dioxa-3-phosphadecalins as inhibitors of acetylcholinesterase. A reappraisal of kinetic mechanisms and diagnostic methods. Chem. Biodivers. 6, 261-282 (2009).
21. Speciale, G., Thompson, A.J., Davies, G.J. & Williams, S.J. Dissecting conformational contributions to glycosidase catalysis and inhibition. Curr. Opin. Struct. Biol. 28, 1-13 (2014).
22. Gloster, T.M. & Davies, G.J. Glycosidase inhibition: assessing mimicry of the transition state. Org. Biomol. Chem. 8, 305-320 (2010).
23. Islam, M.R., Grubb, J.H. & Sly, W.S. C-terminal processing of human beta-glucuronidase. The propeptide is required for full expression of catalytic activity, intracellular retention, and proper phosphorylation. J. Biol. Chem. 268, 22627-22633 (1993).
24. Ono, M. et al. Phosphorylation of beta-glucuronidases from human normal liver and hepatoma by cAMP-dependent protein kinase. J. Biol. Chem. 263, 5884-5889 (1988).
25. Forrest, A.R. et al. A promoter-level mammalian expression atlas. Nature 507, 462-470 (2014).
26. Weiss, D.J., Liggitt, D. & Clark, J.G. Histochemical discrimination of endogenous mammalian beta-galactosidase activity from that resulting from lac-Z gene expression. Histochem. J. 31, 231-236 (1999).
27. Peterson, S.B. & Liu, J. Multi-faceted substrate specificity of heparanase. Matrix Biol. 32, 223-227 (2013).
28. Fairbanks, M.B. et al. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J. Biol. Chem. 274, 29587-29590 (1999).
29. Abboud-Jarrous, G. et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J. Biol. Chem. 283, 18167-18176 (2008).
30. Takahashi, K. et al. Characterization of CAA0225, a novel inhibitor specific for cathepsin L, as a probe for autophagic proteolysis. Biol. Pharm. Bull. 32, 475-479 (2009).
31. Shaw, E., Mohanty, S., Colic, A., Stoka, V. & Turk, V. The affinity-labelling of cathepsin S with peptidyl diazomethyl ketones. Comparison with the inhibition of cathepsin L and calpain. FEBS Lett. 334, 340-342 (1993).
32. Nadav, L. et al. Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J. Cell Sci. 115, 2179-2187 (2002).
33. Vlodavsky, I. et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12, 112-127 (1992).
34. McKenzie, E. et al. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem. J. 373, 423-435 (2003).
35. Islam, M.R. et al. Active site residues of human beta-glucuronidase. Evidence for Glu(540) as the nucleophile and Glu(451) as the acid-base residue. J. Biol. Chem. 274, 23451-23455 (1999).
36. Kallemeijn, W.W. et al. A sensitive gel-based method combining distinct cyclophellitol-based probes for the identification of acid/base residues in human retaining β-glucosidases. J. Biol. Chem. 289, 35351-35362 (2014).
37. Niphakis, M.J. & Cravatt, B.F. Enzyme inhibitor discovery by activity-based protein profiling. Annu. Rev. Biochem. 83, 341-377 (2014).
38. Kawase, Y. et al. A-72363 A-1, A-2, and C, novel heparanase inhibitors from Streptomyces nobilis SANK 60192, II. Biological activities. J. Antibiot. (Tokyo) 49, 61-64 (1996).
39. Rabenstein, D.L. Heparin and heparan sulfate: structure and function. Nat. Prod. Rep. 19, 312-331 (2002).
40. Davies, G.J., Wilson, K.S. & Henrissat, B. Nomenclature for sugar-binding subsites in glycosyl hydrolases. Biochem. J. 321, 557-559 (1997).
41. Bohlmann, L. et al. Functional and structural characterization of a heparanase. Nat. Chem. Biol. 11, 955-957 (2015).
42. Abboud-Jarrous, G. et al. Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J. Biol. Chem. 280, 13568-13575 (2005).
43. Gingis-Velitski, S. et al. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J. Biol. Chem. 279, 44084-44092 (2004).
44. Moreland, R.J. et al. Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J. Biol. Chem. 280, 6780-6791 (2005).
45. Tollersrud, O.K. et al. Purification of bovine lysosomal alpha-mannosidase, characterization of its gene and determination of two mutations that cause alpha-mannosidosis. Eur. J. Biochem. 246, 410-419 (1997).
46. Li, K.-Y. Synthesis of cyclophellitol, dyclophellitol aziridine, and their tagged derivatives. European J. Org. Chem. 6030-6043 (2014).
47. Zheng, L., Baumann, U. & Reymond, J.L. An efficient one-step site-directed and site-saturation mutagenesis protocol. Nucleic Acids Res. 32, e115 (2004).
48. Li, M.Z. & Elledge, S.J. SLIC: a method for sequence- and ligation-independent cloning. Methods Mol. Biol. 852, 51-59 (2012).
49. Berger, I., Fitzgerald, D.J. & Richmond, T.J. Baculovirus expression system for heterologous multiprotein complexes. Nat. Biotechnol. 22, 1583-1587 (2004).
50. Seiler, C.Y. et al. DNASU plasmid and PSI:Biology-Materials repositories: resources to accelerate biological research. Nucleic Acids Res. 42, D1253-D1260 (2014).
51. Li, N. et al. Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS. Nat. Protoc. 8, 1155-1168 (2013).
52. D'Arcy, A., Bergfors, T., Cowan-Jacob, S.W. & Marsh, M. Microseed matrix screening for optimization in protein crystallization: what have we learned? Acta Crystallogr. F Struct. Biol. Commun. 70, 1117-1126 (2014).
53. Winter, G. xia2: an expert system for macromolecular crystallography data reduction. J. Appl. Crystallogr. 43, 186-190 (2010).
54. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
55. Evans, P.R. & Murshudov, G.N. How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204-1214 (2013).
56. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66, 22-25 (2010).
57. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
58. Murshudov, G.N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367 (2011).
59. Lebedev, A.A. et al. JLigand: a graphical tool for the CCP4 template-restraint library. Acta Crystallogr. D Biol. Crystallogr. 68, 431-440 (2012).
60. McNicholas, S., Potterton, E., Wilson, K.S. & Noble, M.E.M. Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr. D Biol. Crystallogr. 67, 386-394 (2011).